SCHEMBL22889161

SCHEMBL22889161

c1ccc(-c2nc(-c3ccc(-c4ccccc4-c4c(-c5ccccc5)ccc5ccccc45)cc3)nc(-c3cccc4c3sc3ccccc34)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.41
MAPT P10636 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
L3MBTL1 Q9Y468 3/20 0.36
TSHR P16473 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
NFKB1 P19838 1/20 0.36
MAPK1 P28482 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36
ATM Q13315 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PARP14 Q460N5 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ALOX15 P16050 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22888713 0.97 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304520 0.95 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304746 0.95 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL22888683 0.94 ALOX5 (0.42) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304325 0.94 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304341 0.94 ALOX5 (0.38) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL22889430 0.94 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL25047305 0.94 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304740 0.93 ALOX5 (0.40) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR
SCHEMBL21304528 0.93 ALOX5 (0.41) ALOX5MAPTSMN1; SMN2L3MBTL1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11765972-B2 Compound and organic electroluminescence device using the same IDEMITSU KOSAN CO., LTD. (JP) 2023-09-19 US disclosed
US-11765972-B2 Compound and organic electroluminescence device using the same IDEMITSU KOSAN CO., LTD. (JP) 2023-09-19 US disclosed
US-20210009527-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME IDEMITSU KOSAN CO.,LTD. (JP) 2021-01-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210009527-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENCE DEVICE USING THE SAME OR10J3, RPS4Y1, AR ALOX5 3163/4885MAPT 2178/4885SMN1; SMN2 2648/4885
US-11765972-B2 Compound and organic electroluminescence device using the same AR, OR10J3, RPS4Y1 ALOX5 3071/4885MAPT 2233/4885SMN1; SMN2 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.